ÌÇÐÄ´«Ã½

Skip to main content
 
Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
ÌÇÐÄ´«Ã½

Neuronal a-Synuclein Disease Stage Progression over 5?Years.

ÌÇÐÄ´«Ã½

Neuronal a-Synuclein Disease Stage Progression over 5?Years. Movement disorders : official journal of the Movement Disorder Society Simuni, T., Gochanour, C., Nair, A. R., Brumm, M. C., Coffey, C., Poston, K. L., Chahine, L. M., Weintraub, D., Tanner, C. M., Gonzalez-Latapi, P., Kopil, C. M., Xiao, Y., Chowdhury, S., Dam, T., Pagano, G., Stephenson, D., Siderowf, A., Dunn, B., Marek, K. 2025

Abstract

Neuronal a-synuclein disease (NSD) is defined by the presence of an in vivo biomarker of neuronal alpha-synuclein (n-asyn) pathology. The NSD integrated staging system (NSD-ISS) for ÌÇÐÄ´«Ã½ describes progression across the disease continuum as stages 0 to 6.The aim was to assess 5-year longitudinal change in NSD-ISS in early disease.Analysis included a subset of participants from the Parkinson's Progression Markers Initiative (PPMI) enrolled before 2020 as Parkinson's disease (PD) patients, prodromal PD patients, or healthy controls (HC) who met NSD criteria. Staging was defined based on biomarkers of n-asyn and dopaminergic dysfunction in early stages, clinical features, and severity of functional impairment in stages 3 to 6. Stages were determined annually for 5?years.Of 576 NSD participants, 494 were enrolled as PD patients, 74 prodromal PD patients, and 8 HCs. At baseline, 24% of participants were stage 2B, 56% Stage 3, 13% stage 4, and less than 5% in other stages. At year 5, the respective percentages for stages 2B to 4 were 11%, 50%, and 34%, indicating progression through NSD stages. Progression was driven by functional impairment in the predominantly motor domain (95%) for stage 2B to 3, increasing degree of nonmotor dysfunction for stages 3 to 4 (46%), and a combination of domains for stages 4 to 5. Initiation of dopaminergic medications led to stage regression in 8% of participants in Stage 3 but 41% in stage 4.Our analysis supports the utility of NSD-ISS in defining the stages of disease progression, at least in the early clinical and prodromal stages (2B, 3, or 4), suggesting the value of NSD-ISS as a potential ÌÇÐÄ´«Ã½ tool for drug development. Further ÌÇÐÄ´«Ã½ involving preclinical cohorts is a crucial next step. © 2025 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

View details for

View details for